Aripiprazole improves social interaction in taiwanese children with pervasive developmental disorder

Chang Gung Medical Journal

Volumn 33, Issue 2, 2010, Pages 211-215

  Huang, Shu Chi ^a   Tsai, Shih Jen ^b,c   Yang, Hao Jan ^d  

^a CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Aripiprazole; Attention; Pervasive developmental disorders; Social interaction

Indexed keywords

AMFEBUTAMONE; ARIPIPRAZOLE; ATOMOXETINE; FLUOXETINE; METHYLPHENIDATE;

ABSENCE OF SIDE EFFECTS; ANOREXIA; ANXIETY; ARTICLE; AUTISM; BEHAVIOR DISORDER; CASE REPORT; CHILD; CLINICAL FEATURE; DEPRESSION; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVENING DOSAGE; HUMAN; MALE; MORNING DOSAGE; PSYCHOMOTOR RETARDATION; REPEATED DRUG DOSE; SCHOOL CHILD; SOCIAL INTERACTION; TAIWAN; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTIPSYCHOTIC AGENTS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; HUMANS; MALE; PIPERAZINES; QUINOLONES; TAIWAN;

EID: 77951761660     PISSN: 20720939     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Goodnick PJ, Jerry JM. Aripiprazole: profile on efficacy and safety. Expert Opin Pharmacother 2002;3:1773-81.
2. Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2004;64:1715-36.
3. Biederman J, McDonnell MA, Wozniak J, Spencer T, Aleardi M, Falzone R, Mick E. Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review. CNS Spectr 2005;10:141-8.
4. Murphy TK, Bengtson MA, Soto O, Edge PJ, Sajid MW, Shapira N, Yang M. Case series on the use of aripiprazole for Tourette syndrome. Int J Neuropsychopharmacol 2005;8:489-90.
5. Dinca O, Paul M, Spencer NJ. Systematic review of randomized controlled trials of atypical antipsychotics and selective serotonin reuptake inhibitors for behavioural problems associated with pervasive developmental disorders. J Psychopharmacol 2005;19:521-32.
6. Stigler KA, Posey DJ, McDougle CJ. Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol 2004;14:455-63.
7. Valicenti-McDermott MR, Demb H. Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. J Child Adolesc Psychopharmacol 2006;16:549-60.
8. Karunakaran K, Tungaraza TE, Harborne G. Is clozapinearipiprazole combination a useful regime in the management of treatment-resistant schizophrenia? J Psychopharmacol 2007;21:453-6.
9. Bruins Slot LA, Kleven MS, Newman-Tancredi A. Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat. Neuropharmacology 2005;49:996-1006.
10. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002;441:137-40.
11. Worthington JJ 3rd, Kinrys G, Wygant LE, Pollack MH. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol 2005;20:9-11.
12. Agmo A, Soria P. The duration of the effects of a single administration of dopamine antagonists on ambulatory activity and motor coordination. J Neural Transm 1999;106:219-27.
13. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors. J Clin Psychiatry 2001;62:841-2.